Fragmented sources
More feeds. More formats.
Different schemas, biomarker names, result formats, and provider fields create work each time a source is added or changed.
A relevant result is only the beginning. Connect laboratory signals, patient context, and provider intelligence to help your team understand the opportunity—and evaluate whom to engage.
Illustrative workflow. Available attributes and enrichment vary by source and program.
Liquid biopsy, solid-tissue, and specialty testing can reveal important clinical signals. Turning those signals into useful commercial intelligence requires a consistent view of the result, the patient, and the provider.
Different schemas, biomarker names, result formats, and provider fields create work each time a source is added or changed.
Assay, methodology, and scoring context help teams interpret available biomarker information and use it consistently.
A lab record may name an ordering pathologist rather than the oncologist managing the patient. Additional provider context can help teams evaluate whom to engage.
Prognos Fusion combines data licensed through Prognos with participating directly contracted lab feeds, applies harmonization and enrichment, and delivers a consistent structure for your workflow.
Combine liquid biopsy, solid-tissue, and other relevant laboratory sources within the licensed program scope.
The HCP listed on a laboratory record may not be the provider your commercial team needs to understand.
Prognos adds linked patient and provider context to help identify relevant treating providers and reveal a broader care network. That gives your team more information to assess HCP relevance before planning engagement.
Explore Care Team enrichment →Patient linkage + observed provider activity + clinical context
Provider identification depends on available source data and linkage. Observed HCP activity does not, by itself, confirm a disease-specific treating role.
A global pharmaceutical company used Prognos Fusion to operationalize multiple lab feeds for biomarker-defined patient identification and HCP activation.
Data licensed through Prognos and directly contracted lab feeds brought into a consistent program.
Provider enrichment helped the program surface more active-provider intelligence from the connected data.
Additional provider visibility for the team to evaluate alongside its existing targeting foundation.
Standardized clinical content, deduplicated overlapping patients and results, and applied provider enrichment across the participating feeds.
Managed ongoing schema and test-menu changes to support consistent delivery as the underlying sources evolved.
Source: Prognos Fusion Oncology Case Study, July 2026, as summarized in the supplied oncology brief. Results describe this specific program and are not forecasts or guarantees for another account.
Bring a priority tumor type or biomarker. We can evaluate relevant testing sources, available clinical attributes, provider context, linkage needs, and delivery options.
Bring biomarker results and available clinical context into cohort definition and market understanding.
Use relevant laboratory events to support alert programs and inform follow-up in your existing environment.
Evaluate enriched provider intelligence and incremental NPI visibility alongside current targeting tables.
Bring clinical signals and provider context into your team's field and omnichannel decision workflows.
Datavant tokenization supports linkage with compatible patient-level data assets, subject to permissions and source availability.
Coverage, clinical attributes, linkage, and provider identification vary by indication, assay, source data, and program scope. Tumor types shown are examples for discussion.
Fusion can integrate participating directly contracted lab feeds alongside data licensed through Prognos, within the agreed permissions and program scope.
Available markers, results, methodologies, and clinical terminology are harmonized with assay and scoring context. The attributes available depend on the indication, assay, and source data.
Provider enrichment adds linked patient and provider context to help identify relevant treating HCPs. Identification depends on available data and linkage; observed activity alone does not confirm a disease-specific treating role.
The blinded case study used one daily delivery. For a new program, the delivery structure and cadence are aligned to the intended workflow and available sources.
Tell us what your current data captures, which patients and providers you need to understand, and where additional sources or enrichment could contribute.